Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay

Alba Torres, Mohammed Alshalalfa, Scott A. Tomlins, Nicholas Erho, Ewan A. Gibb, Jijumon Chelliserry, Lony Lim, Lucia L.C. Lam, Sheila F. Faraj, Stephania M. Bezerra, Elai Davicioni, Kasra Yousefi, Ashley E. Ross, George J. Netto, Edward M. Schaeffer, Tamara Lotan

Research output: Contribution to journalArticle

Abstract

ETS family gene fusions are common in prostate cancer and molecularly define a tumor subset. ERG is the most commonly rearranged, leading to its overexpression, followed by ETV1, ETV4, and ETV5, and these alterations are generally mutually exclusive. We validated the Decipher prostate cancer assay to detect ETS alterations in a Clinical Laboratory Improvement Amendments–accredited laboratory. Benchmarking against ERG immunohistochemistry and ETV1/4/5 RNA in situ hybridization, we examined the accuracy, precision, and reproducibility of gene expression ETS models using formalin-fixed, paraffin-embedded samples. The m-ERG model achieved an area under curve of 95%, with 93% sensitivity and 98% specificity to predict ERG immunohistochemistry status. The m-ETV1, -ETV4, and -ETV5 models achieved areas under curve of 98%, 88%, and 99%, respectively. The models had 100% robustness for ETS status, and scores were highly correlated across sample replicates. Models predicted 41.5% of a prospective radical prostatectomy cohort (n = 4036) to be ERG+, 6.3% ETV1+, 1% ETV4+, and 0.4% ETV5+. Of prostate tumor biopsy samples (n = 509), 41.2% were ERG+, 8.6% ETV1+, 0.4% ETV4+, and none ETV5+. Higher Decipher risk status tumors were more likely to be ETS+ (ERG or ETV1/4/5) in the radical prostatectomy and the biopsy cohorts (P < 0.05). These results support the utility of microarray-based ETS status prediction models for molecular classification of prostate tumors.

Original languageEnglish (US)
Pages (from-to)475-484
Number of pages10
JournalJournal of Molecular Diagnostics
Volume19
Issue number3
DOIs
StatePublished - May 1 2017

Fingerprint

Prostate
Prostatectomy
Genes
Area Under Curve
Neoplasms
Prostatic Neoplasms
Immunohistochemistry
Biopsy
Benchmarking
Molecular Models
Gene Fusion
Paraffin
Formaldehyde
In Situ Hybridization
RNA
Gene Expression
Sensitivity and Specificity

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. / Torres, Alba; Alshalalfa, Mohammed; Tomlins, Scott A.; Erho, Nicholas; Gibb, Ewan A.; Chelliserry, Jijumon; Lim, Lony; Lam, Lucia L.C.; Faraj, Sheila F.; Bezerra, Stephania M.; Davicioni, Elai; Yousefi, Kasra; Ross, Ashley E.; Netto, George J.; Schaeffer, Edward M.; Lotan, Tamara.

In: Journal of Molecular Diagnostics, Vol. 19, No. 3, 01.05.2017, p. 475-484.

Research output: Contribution to journalArticle

Torres, A, Alshalalfa, M, Tomlins, SA, Erho, N, Gibb, EA, Chelliserry, J, Lim, L, Lam, LLC, Faraj, SF, Bezerra, SM, Davicioni, E, Yousefi, K, Ross, AE, Netto, GJ, Schaeffer, EM & Lotan, T 2017, 'Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay', Journal of Molecular Diagnostics, vol. 19, no. 3, pp. 475-484. https://doi.org/10.1016/j.jmoldx.2017.01.007
Torres, Alba ; Alshalalfa, Mohammed ; Tomlins, Scott A. ; Erho, Nicholas ; Gibb, Ewan A. ; Chelliserry, Jijumon ; Lim, Lony ; Lam, Lucia L.C. ; Faraj, Sheila F. ; Bezerra, Stephania M. ; Davicioni, Elai ; Yousefi, Kasra ; Ross, Ashley E. ; Netto, George J. ; Schaeffer, Edward M. ; Lotan, Tamara. / Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. In: Journal of Molecular Diagnostics. 2017 ; Vol. 19, No. 3. pp. 475-484.
@article{631d04c234e54793b931c2b706ce4c5e,
title = "Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay",
abstract = "ETS family gene fusions are common in prostate cancer and molecularly define a tumor subset. ERG is the most commonly rearranged, leading to its overexpression, followed by ETV1, ETV4, and ETV5, and these alterations are generally mutually exclusive. We validated the Decipher prostate cancer assay to detect ETS alterations in a Clinical Laboratory Improvement Amendments–accredited laboratory. Benchmarking against ERG immunohistochemistry and ETV1/4/5 RNA in situ hybridization, we examined the accuracy, precision, and reproducibility of gene expression ETS models using formalin-fixed, paraffin-embedded samples. The m-ERG model achieved an area under curve of 95{\%}, with 93{\%} sensitivity and 98{\%} specificity to predict ERG immunohistochemistry status. The m-ETV1, -ETV4, and -ETV5 models achieved areas under curve of 98{\%}, 88{\%}, and 99{\%}, respectively. The models had 100{\%} robustness for ETS status, and scores were highly correlated across sample replicates. Models predicted 41.5{\%} of a prospective radical prostatectomy cohort (n = 4036) to be ERG+, 6.3{\%} ETV1+, 1{\%} ETV4+, and 0.4{\%} ETV5+. Of prostate tumor biopsy samples (n = 509), 41.2{\%} were ERG+, 8.6{\%} ETV1+, 0.4{\%} ETV4+, and none ETV5+. Higher Decipher risk status tumors were more likely to be ETS+ (ERG or ETV1/4/5) in the radical prostatectomy and the biopsy cohorts (P < 0.05). These results support the utility of microarray-based ETS status prediction models for molecular classification of prostate tumors.",
author = "Alba Torres and Mohammed Alshalalfa and Tomlins, {Scott A.} and Nicholas Erho and Gibb, {Ewan A.} and Jijumon Chelliserry and Lony Lim and Lam, {Lucia L.C.} and Faraj, {Sheila F.} and Bezerra, {Stephania M.} and Elai Davicioni and Kasra Yousefi and Ross, {Ashley E.} and Netto, {George J.} and Schaeffer, {Edward M.} and Tamara Lotan",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.jmoldx.2017.01.007",
language = "English (US)",
volume = "19",
pages = "475--484",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "3",

}

TY - JOUR

T1 - Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay

AU - Torres, Alba

AU - Alshalalfa, Mohammed

AU - Tomlins, Scott A.

AU - Erho, Nicholas

AU - Gibb, Ewan A.

AU - Chelliserry, Jijumon

AU - Lim, Lony

AU - Lam, Lucia L.C.

AU - Faraj, Sheila F.

AU - Bezerra, Stephania M.

AU - Davicioni, Elai

AU - Yousefi, Kasra

AU - Ross, Ashley E.

AU - Netto, George J.

AU - Schaeffer, Edward M.

AU - Lotan, Tamara

PY - 2017/5/1

Y1 - 2017/5/1

N2 - ETS family gene fusions are common in prostate cancer and molecularly define a tumor subset. ERG is the most commonly rearranged, leading to its overexpression, followed by ETV1, ETV4, and ETV5, and these alterations are generally mutually exclusive. We validated the Decipher prostate cancer assay to detect ETS alterations in a Clinical Laboratory Improvement Amendments–accredited laboratory. Benchmarking against ERG immunohistochemistry and ETV1/4/5 RNA in situ hybridization, we examined the accuracy, precision, and reproducibility of gene expression ETS models using formalin-fixed, paraffin-embedded samples. The m-ERG model achieved an area under curve of 95%, with 93% sensitivity and 98% specificity to predict ERG immunohistochemistry status. The m-ETV1, -ETV4, and -ETV5 models achieved areas under curve of 98%, 88%, and 99%, respectively. The models had 100% robustness for ETS status, and scores were highly correlated across sample replicates. Models predicted 41.5% of a prospective radical prostatectomy cohort (n = 4036) to be ERG+, 6.3% ETV1+, 1% ETV4+, and 0.4% ETV5+. Of prostate tumor biopsy samples (n = 509), 41.2% were ERG+, 8.6% ETV1+, 0.4% ETV4+, and none ETV5+. Higher Decipher risk status tumors were more likely to be ETS+ (ERG or ETV1/4/5) in the radical prostatectomy and the biopsy cohorts (P < 0.05). These results support the utility of microarray-based ETS status prediction models for molecular classification of prostate tumors.

AB - ETS family gene fusions are common in prostate cancer and molecularly define a tumor subset. ERG is the most commonly rearranged, leading to its overexpression, followed by ETV1, ETV4, and ETV5, and these alterations are generally mutually exclusive. We validated the Decipher prostate cancer assay to detect ETS alterations in a Clinical Laboratory Improvement Amendments–accredited laboratory. Benchmarking against ERG immunohistochemistry and ETV1/4/5 RNA in situ hybridization, we examined the accuracy, precision, and reproducibility of gene expression ETS models using formalin-fixed, paraffin-embedded samples. The m-ERG model achieved an area under curve of 95%, with 93% sensitivity and 98% specificity to predict ERG immunohistochemistry status. The m-ETV1, -ETV4, and -ETV5 models achieved areas under curve of 98%, 88%, and 99%, respectively. The models had 100% robustness for ETS status, and scores were highly correlated across sample replicates. Models predicted 41.5% of a prospective radical prostatectomy cohort (n = 4036) to be ERG+, 6.3% ETV1+, 1% ETV4+, and 0.4% ETV5+. Of prostate tumor biopsy samples (n = 509), 41.2% were ERG+, 8.6% ETV1+, 0.4% ETV4+, and none ETV5+. Higher Decipher risk status tumors were more likely to be ETS+ (ERG or ETV1/4/5) in the radical prostatectomy and the biopsy cohorts (P < 0.05). These results support the utility of microarray-based ETS status prediction models for molecular classification of prostate tumors.

UR - http://www.scopus.com/inward/record.url?scp=85018478672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018478672&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2017.01.007

DO - 10.1016/j.jmoldx.2017.01.007

M3 - Article

C2 - 28341589

AN - SCOPUS:85018478672

VL - 19

SP - 475

EP - 484

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 3

ER -